The vertical lanes on the left are live research fronts, each with its own learning module. The boxes on the right are the four named AIHS bottlenecks — the problems the feasibility study (S-001) singled out as genuinely hard — plus one capability node (drawn dashed): Bucket C therapeutic execution, which is where the "build and deliver the intervention" fronts belong. It is deliberately marked as a capability area, not a named bottleneck, so the map never implies it is one. A line is drawn only where a front makes a direct contribution — no second-order stretches — and every line is flagged: its colour records how mature that contribution is today, using the same four-flag system as the rest of the site. Hover or tab to any front or box to trace its connections.
Trace the convergence
Frontier Read it in three parts. The virtual cell is the sole feeder of A2 (molecular mapping) and B3 (causal disease modelling) — one maturing front carrying both diagnostic bottlenecks. Therapeutic execution (the dashed C node — a Bucket-C capability, not a named bottleneck) is crowded: protein design, in-vivo editing, and reprogramming all land there at the frontier. Speculative The two hardest named therapeutic bottlenecks are fed most thinly — C4 (neural reconnection) by neural interfaces that bypass the injury (Frontier) and reprogramming that would regrow it (Speculative, dashed), and C7 by molecular machines alone (Speculative). Where the lines are thinnest and most dashed is exactly where the science is least settled — the map is built to show that, not hide it.
Established One reading of this map is optimistic and one is sober, and both are true. The optimistic reading: problems that looked like isolated science-fiction premises a few years ago now each have a named research front pushing on them, and several of those fronts have crossed from speculation into the frontier. The sober reading: the hardest nodes are still fed mostly by dashed lines, and a line on a map is not a solved problem.
The study's core stance holds here too: convergence delivers real value even where the hardest nodes never fully yield. A system that maps molecular state and models disease well (B3, A2) but only bypasses rather than regrows neural damage (C4) is still transformative medicine. The map is a picture of momentum, not a promise of completion.